Given the role of SGLT-2 in glucose transport, selective SGLT-2 inhibitor developed as a new class of oral anti-hyperglycemic agents available for treatment of T2DM without influence of pancreas islet function and risk of hypoglycemia (Idris and Donnelly, 2009). The gene discussed is SLC5A2; the disease is Hypoglycemia.